Akorn (AKRX) : 10 analysts are covering Akorn (AKRX) and their average rating on the stock is 1.9, which is read as a Buy. 5 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Akorn (AKRX) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 4 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Akorn (AKRX) : The most positive equity analysts on Akorn (AKRX) expects the shares to touch $40, whereas, the least positive believes that the stock will trade at $31 in the short term. The company is covered by 8 Wall Street Brokerage Firms. The average price target for shares are $35.75 with an expected fluctuation of $3.33 from the mean.
Akorn, Inc. has lost 1.14% in the last five trading days and dropped 11.18% in the last 4 weeks. Akorn, Inc. has dropped 4.81% during the last 3-month period . Year-to-Date the stock performance stands at -21.01%. Akorn (NASDAQ:AKRX): On Tuesdays trading session , Opening price of the stock was $29.68 with an intraday high of $29.99. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $29.375. However, the stock managed to close at $29.47, a loss of 0.17% for the day. On the previous day, the stock had closed at $29.52. The total traded volume of the day was 813,388 shares.
Akorn Inc. (Akorn), together with its wholly owned subsidiaries, is a specialty pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as animal and over-the-counter (OTC) consumer health products. The Company specializes in sterile and non-sterile dosage forms, including ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays. The Company operates in two segments: Prescription Pharmaceuticals, which is engaged in the sale of branded and generic prescription pharmaceuticals, and Consumer Health, which is engaged in the sale of branded and private label consumer and animal health products. The Company operates pharmaceutical manufacturing facilities in Decatur, Illinois; Somerset, New Jersey; Amityville, New York, and Paonta Sahib, Himachal Pradesh, India, as well as a central distribution warehouse in Gurnee, Illinois, and an additional warehousing facility in Amityville, New York.